FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1370-1371 September 28, 2006 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Morton, D. L. PubMed Citation

In this issue of the Journal, Morton and colleagues report the largest and most important trial of sentinel-lymph-node biopsy for melanoma conducted to date.¹ In the trial, 1269 patients with intermediate-thickness (1.2 to 3.5 mm) melanoma were randomly assigned to immediate sentinel-node biopsy or to observation for clinically detectable (palpable) lymph nodes draining the site of the melanoma. If the biopsy showed microscopical metastases, patients underwent immediate radical lymphadenectomy. In the observation group, lymphadenectomy was performed only after palpable lymph nodes were detected. The trial clearly demonstrates that sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases . . . [Full Text of this Article]

Source Information

From the Johns Hopkins Medical Institutions, Baltimore (C.M.B.); and the National Tumor Institute, Milan (N.C.).

Related Letters:

Sentinel-Node Biopsy in Melanoma
Thomas J. M., A'Hern R. P., Grichnik J. M., Retsas S., Lipsker D., Kanzler M. H., Levitt L., Lin A., Morton D. L., Cochran A. J., Thompson J. F., Balch C. M., Cascinelli N.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:418-421, Jan 25, 2007. Correspondence

This article has been cited by other articles:

• Bilimoria, K. Y., Balch, C. M., Wayne, J. D., Chang, D. C., Palis, B. E., Dy, S. M., Lange, J. R. (2009). Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States. JCO 27: 1857-1863 [Abstract] [Full Text]  
• Grange, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F., Michel, C., Batard, M.-L., Baury, B., Halna, J.-M., Schmutz, J. L., Delvincourt, C., Reuter, G., Dalle, S., Bernard, P., Danzon, A. (2008). Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France. Arch Dermatol 144: 629-636 [Abstract] [Full Text]  
• Niakosari, F., Kahn, H. J., McCready, D., Ghazarian, D., Rotstein, L. E., Marks, A., Kiss, A., From, L. (2008). Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma. Arch Dermatol 144: 462-467 [Abstract] [Full Text]  
• Retsas, S. (2007). Sentinel node biopsy confers no added protection to patients with melanoma. JRSM 100: 391-392 [Full Text]  
• Kanzler, M. H. (2007). The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive. Arch Dermatol 143: 785-787 [Full Text]  
• Thomas, J. M., A'Hern, R. P., Grichnik, J. M., Retsas, S., Lipsker, D., Kanzler, M. H., Levitt, L., Lin, A., Morton, D. L., Cochran, A. J., Thompson, J. F., Balch, C. M., Cascinelli, N. (2007). Sentinel-Node Biopsy in Melanoma. NEJM 356: 418-421 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals. BMJ 333: 744-745 [Full Text]  
• (2006). The Prognosis for Sentinel Lymph Node Biopsies. Journal Watch Dermatology 2006: 1-1 [Full Text]